Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial.
Naveen ReddyPramod ReddyAnkit RanpuraNarendra MaharajRajendersingh AroraGopichand MamillapalliAditya Shirish AdhavAshok Kumar DiwanAlexey ManikhasDmitriy KrasnozhonPublished in: JCO global oncology (2024)
DRL_TZ was found to have similar efficacy and comparable safety, PK, and immunogenicity profiles as the RMP.